Open AccessNeoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol
Author(s) -
Yoshihiro Miyasaka,
Takao Ohtsuka,
Susumu Eguchi,
Masafumi Ito,
Kazuyoshi Nishihara,
Hiroyuki Shinchi,
K Okuda,
Hideo Baba,
Hiroaki Nagano,
Toshiharu Ueki,
Hirokazu Noshirο,
Masafumi Nakamura
Publication year - 2021
Publication title -
international journal of surgery protocols
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.291
H-Index - 4
ISSN - 2468-3574
DOI - 10.29337/ijsp.142
Subject(s) - gemcitabine , medicine , regimen , pancreatic cancer , neoadjuvant therapy , oncology , chemotherapy , clinical endpoint , cancer , breast cancer , clinical trial
Although neoadjuvant treatment is recommended for patients with borderline resectable pancreatic cancer (BRPC), no standard neoadjuvant regimen has been established for BRPC with arterial involvement (BRPC-A), which is associated with a higher risk of margin-positive resection and poorer prognosis than BRPC with only venous involvement. Gemcitabine plus nab-paclitaxel (GnP) has been reported to significantly reduce tumor size in metastatic pancreatic cancer, and some retrospective studies suggested that neoadjuvant GnP for BRPC improved resectability and survival.